Ceftobiprole

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Staphylococcal Skin Infections

Conditions

Staphylococcal Skin Infections, Streptococcal Infections

Trial Timeline

Jun 1, 2007 → Sep 1, 2007

NCT ID

NCT01026740

About Ceftobiprole

Ceftobiprole is a phase 1 stage product being developed by Basilea Pharmaceutica for Staphylococcal Skin Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01026740. Target conditions include Staphylococcal Skin Infections, Streptococcal Infections.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00965042	Phase 1	Completed	Apr 1, 2009	Jun 1, 2009	Antimicrobial Agent
NCT00771524	Phase 1	Completed	Apr 1, 2009	Feb 1, 2010	Total Hip Replacement Surgery
NCT00771719	Phase 1	Terminated	Oct 1, 2008	Nov 1, 2009	Ventilator Associated Pneumonia
NCT01026740	Phase 1	Completed	Jun 1, 2007	Sep 1, 2007	Staphylococcal Skin Infections

Competing Products

20 competing products in Staphylococcal Skin Infections

See all competitors

Product	Company	Stage	Hype Score
Ceftobiprole	Johnson & Johnson	Phase 1	33
Ceftobiprole	Johnson & Johnson	Phase 1	33
Daptomycin + Vancomycin	Merck	Approved	85
Daptomycin 4 mg/kg + Comparator: vancomycin + Daptomycin 6 mg/kg	Merck	Phase 3	77
V710 + Placebo	Merck	Phase 1	33
V710 + Comparator: Placebo	Merck	Phase 1	33
V710 (30 µg) with MAA + V710 (30 µg) without MAA	Merck	Phase 1	33
Daptomycin + Vancomycin	Merck	Approved	85
Daptomycin	Novartis	Approved	85
SA4Ag vaccine	Pfizer	Phase 1	32
Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine	Pfizer	Phase 2	51
linezolid (Zyvox)	Pfizer	Pre-clinical	22
Staphylococcus aureus 4-antigen vaccine + Placebo	Pfizer	Phase 2	51
Tigecycline	Pfizer	Approved	84
SA4Ag vaccine low dose + SA4Ag vaccine mid dose + SA4Ag vaccine high dose + Placebo	Pfizer	Phase 1	32
SA4Ag vaccine low dose + SA4Ag vaccine mid dose + SA4Ag vaccine high dose + SA3Ag vaccine + Placebo	Pfizer	Phase 1	32
NDV-3 vaccine with alum IM + NDV-3 vaccine without alum IM + Placebo with alum IM + NDV-3 vaccine without alum ID	United Therapeutics	Phase 1	30
NDV-3 investigational vaccine	United Therapeutics	Phase 1	30
TD-1792 + Vancomycin	Theravance Biopharma	Phase 2	47
human lactoferrin peptide 1-11	AM-Pharma	Phase 1/2	33

Other Products from Basilea Pharmaceutica

alitretinoinPhase 3

ceftobiprole medocaril + vancomycin+aztreonamPhase 3

alitretinoinPhase 3

Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + PlaceboPhase 3

ceftobiprole medocaril + Vancomycin plus CeftazidimePhase 3